Patients with chronic liver disease often have varying degrees of hepatic fibrosis, and further exacerbations can lead to cirrhosis and even hepatocellular carcinoma. Liver biopsy is the gold standard for the diagnosis of liver fibrosis/cirrhosis, but there are still many limitations. In recent years, non-invasive assessments for liver fibrosis/cirrhosis have gained rapid development. Of these techniques, two different approaches have been validated in clinical practice: imaging methods based on the measurement of liver stiffness, and biological methods based on the serum biomarkers. The two different approaches can complement each other. Current non-invasive assessments for liver fibrosis/cirrhosis tend to be reliable for the detection of advanced fibrosis and cirrhosis, but often lack to distinguish the different early stage of liver fibrosis. Further improving the accuracy of non-invasive assessments might play an important role for clinical management of liver diseases.
慢性肝病患者通常伴随不同程度肝纤维化，进一步加重可致肝硬化，甚至肝细胞癌。肝活组织检是肝纤维化/肝硬化诊断的金标准，但尚有不少局限。近年来，肝纤维化/肝硬化无创评估技术受到越来越多的关注。当前在临床中应用的无创评估技术分为2类：测量肝脏硬度值的影像学方法和基于血清学指标的评分模型方法。联合血清学与影像学方法可以起互补作用。肝纤维化/肝硬化无创评估技术能很好地区分显著肝纤维化/肝硬化与无显著肝纤维化的患者，但往往难以进行早期肝纤维化的分期。进一步提高无创评估技术的准确性对临床管理肝脏疾病具有重要意义。.
Keywords: Elastography; Liver cirrhosis; Liver fibrosis; Non-invasive assessment; Serology.